Keywords: smithkline, beecham, achieves, earnings, targets, boosted, strong
SmithKline Beecham achieves earnings targets, boosted by strong Seroxat
Article | 17 February 2000
SmithKline Beecham has reached its target of 13% pretax profit growthfor 1999, having posted earnings of L1.94 billion ($3.01 billion) on sales of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
